Charles River launches off-the-shelf lentiviral vector packaging plasmids

Charles River announced the launch of its off-the-shelf lentiviral vector, or LVV, packaging plasmids, providing a streamlined solution to the challenges associated with plasmid sourcing in cell and gene therapies. Cell and gene therapies often rely on plasmid DNA, or pDNA, as a critical starting material. However, production challenges such as capacity bottlenecks and timeline pressures, as well as a need for process development optimization can result in increased lead time, cost and complexity. Charles River’s off-the-shelf packaging plasmids offer an alternative solution to these hurdles with immediate availability, reduced development costs and simplified supply chains that streamline and secure lentiviral vector production. In addition to its off-the-shelf offerings, Charles River provides services to meet customer specific needs such as regulatory requirements or product characteristics. These include viral vector production services ranging from clone construction through good manufacturing practice (GMP) for clinical trials or commercial use.